



Published in final edited form as:

ACS Appl Mater Interfaces. 2019 January 23; 11(3): 2790–2801. doi:10.1021/acsami.8b17808.

Design, Synthesis, and Nanostructure-Dependent Antibacterial Activity of Cationic Peptide Amphiphiles

Nathalia Rodrigues de Almeida^a, Yuchun Han^b, Jesus Perez^c, Sydney Kirkpatrick^d, Yilin Wang^b, Martin Conda Sheridan^a

^aDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.

^bKey Laboratory of Colloid and Interface Science, Beijing National Laboratory for Molecular Sciences (BNLMS), Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, People's Republic of China

^cDepartment of Biology. Creighton University, Omaha, NE 68178, USA

^dPre-Pharmacy. Creighton University, Omaha, NE 68178, USA.

Abstract

The development of bacterial resistant strains is a global health concern. Designing antibiotics that limit the rise of pathogenic resistance is essential to efficiently treat pathogenic infections. Self-assembling amphiphilic molecules are an intriguing platform for the treatment of pathogens due to their ability to disrupt bacterial membranes and function as drug nanocarriers. We have designed cationic peptide amphiphiles (PAs) that can form micelles, nanofibers, and twisted ribbons with the aim of understanding antimicrobial activity at the supramolecular level. We have found that micelle-forming PAs possess excellent antimicrobial activity against various Gram-positive and Gram-negative pathogens, such as methicillin-resistant *S. aureus* and multidrug resistant *K. pneumoniae* with MICs ranging between 1–8 $\mu\text{g}/\text{mL}$ when compared to nanofibers with MICs >32 $\mu\text{g}/\text{mL}$. The data suggest the antimicrobial activity of the PAs depends on their morphology, amino-acids sequence, the length of the alkyl tail, and the overall hydrophobicity of the PA. Scanning electron microscopy, confocal microscopy, and flow cytometry studies using MRSA and *E. coli* K12 strains showed that PAs increase cell membrane permeability, and disrupt the integrity of the pathogen's membrane, leading to cell lysis and death. PAs are a promising platform to develop new antimicrobials that could work as nanocarriers to develop synergistic antibacterial therapies.


Graphical Abstract

Corresponding Author: martin.condasheridan@unmc.edu Tel: +1-402-559-9361.

Supporting Information

PAs chemical structures; MALDI-TOF-MS spectra; HPLC chromatograms; CD spectra; nanostructures TEM micrographs; antibacterial activity in different self-assembling conditions; bacterial killing assay; inhibition of *S. aureus* JE2 biofilms; experimental procedures for minimal inhibitory concentration, cytotoxicity and hemolysis from CO-ADD The University of Queensland (Australia); independent binding model for ITC analysis; additional TEM and SEM for *S. aureus* JE2 and *E. coli* K12; flow cytometry and in vivo antimicrobial assay pictures (PDF).

The authors declare that there are no conflicts of interest.



Keywords

peptide amphiphiles; cationic nanostructures; micelles; antimicrobials; supramolecular structure-activity relationships; self-assembly

1. Introduction

The efficient treatment of infections has been aggravated by the unceasing proliferation of pathogenic resistance. The “nightmare bacteria” is a great health concern, and a cause of social issues for the general population.^{1–4} For example, drug resistant pathogens.^{1, 5} such as *Staphylococci*, *Enterococci*, *Klebsiella pneumoniae*, and *Pseudomonas spp* lead to prolonged illness and risk of death.⁶ In fact, in the United States, around 2 million people are infected each year by resistant pathogens causing over 20,000 annual deaths.³ These “super bugs” are a result of intrinsic resistance to antibiotics, and they acquire resistance via genetic mutations and gene transfer due to the overuse of current antibiotics in agriculture, human, and veterinary medicine.^{2, 7} Therefore, it is important to find new antimicrobial agents that are not affected by traditional mechanisms of bacterial resistance is essential.⁸

Antimicrobial peptides (AMPs) are endogenous molecules found in the innate immune system of humans and other organisms.^{5, 9} Unlike conventional antibiotics that target essential biosynthetic pathways, AMPs provide microbicidal activity by a mechanism of action associated with physical disruption of the pathogen’s membrane, which leads to cell death by leakage of cytoplasmic components.^{10, 11} The development of resistance against AMPs is greatly reduced,^{12, 13} because it is metabolically costly for the bacteria to mutate or repair membrane’s molecular constituents.¹⁴ Nevertheless, AMP-based antimicrobial agents usually suffer drawbacks, such as limited bioavailability and a short half-life due to proteolytic degradation. Self-assembling peptide amphiphiles (PAs) can mimic AMP activity while providing more resistance to proteolytic hydrolysis due to the formation of nanostructures (which may limit enzyme accessibility) and the acylation of their *N*-terminus.¹⁵ PA-based materials are also biocompatible, biodegradable, and possess diverse biological applications.^{16, 17} For example, Niu and co-workers reported lipopeptides with a broad-spectrum of activity against dangerous pathogens such as; multi-drug resistant *S. epidermidis*, MRSA, Vancomycin-resistant *E. faecalis*, and multi-drug resistant (MDR) *P. aeruginosa*.¹⁵ The authors postulated the length of the alkyl-chain tail to be key for the interaction with the membrane and found that unsaturated alkyl tails can decrease hemolytic activity, enhance selectivity, and increase resistance to proteolytic degradation.¹⁵ Shankar *et*

*al.*⁹ reported the antimicrobial activity of lipopeptides assembled into nanofibers and nanoneedles, and hypothesized that different shapes may influence their biological activities. The authors reported that needle-shaped assemblies have high antimicrobial and hemolytic activity, while nanofibers displayed less hemolytic activity and toxicity.⁹

Other studies have indicated that the shape of the nanostructure plays an important role in antimicrobial activity suggesting that spherical nanostructures are more effective antibacterials than rod-like systems.^{9, 12, 18} Intrigued by those precedents, we sought to understand how the shape affects the antibacterial activity of PAs. We designed a series of cationic PAs of different morphologies and investigated the relationship between the shape, charge, and antimicrobial activity. In this report, we demonstrated that PA micelles are more effective antibacterials than nanofibers, showing a broad-spectrum of activity towards various bacteria and fungi, including clinically relevant pathogens such as: MRSA, *K. pneumoniae*, *C. albicans*, and *C. neoformans*. The observed supramolecular structure-activity relationships (SSAR) correlated with parameters such as charge and hydrophobicity with antimicrobial activity and cytotoxicity. Self-assembling PAs that damage the bacterial membrane show strong potential as antimicrobials and may be combined with traditional antibiotics to develop therapies with synergistic antibacterial action.

2. Experimental section

Materials.

Dichloromethane (DCM), *N,N*-dimethylformamide (DMF), and Octadecanoic acid were obtained from Fisher Chemical. The amino acids Fmoc-Lys(Boc)-OH and Fmoc-Orn(Boc)-OH were purchased from Creosalus (Louisville, KY), Fmoc-amino acids and *N,N,N',N'*-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) were purchased from AAPPTec, P3 Biosystems or Novabiochem. Anthracene-9-carboxylic acid, Hexadecanoic and 2-n-Hexyldecanoic acid were obtained from Alfa Ceasar. Rink amide resin was purchased from CreoSaulus (Louisville, KY). *N,N*-diisopropylethylamine (DIPEA) was purchased from Oakwood Chemical and 4-methyl piperidine from Acros Organic. DMEM – high glucose (Hylcone), and Cosmic Calf Serum were obtained from Thermo Scientific, fetal bovine serum, 1% penicillin/streptomycin, and Medium 199 were obtained from Gibco Invitrogen. Hydrocortisone, Sodium Selenite, Apo-Transferrin bovine, Insulin, and Gentamicin were purchased from Sigma Aldrich and Recombinant human EGF from R&D systems. The 96-well flat-bottomed polystyrene microtiter plates (Nunclon Delta Surface) were from Thermo Scientific).

General Procedure for Synthesis and Characterization.

PAs were synthesized manually or using a Focus XC peptide synthesizer (AAPPTec) with standard Fmoc solid-phase peptide chemistry on a 0.28 mmol scale on Rink amide resin following literature reports.^{19–21} All coupling and deprotection steps were done on the Focus XC synthesizer using default settings. Mass spectrometry, to identify the PAs, was done in a SIEEX 4800 MALDI TOF/TOF analyzer (Ontario, Canada). The products were purified using a preparative scale reverse phase HPLC (Agilent) with a C₁₈ column as stationary phase of 5µm, 100 Å pore size and 150 × 21.1 mm (Phonomenex) with a gradient

of ACN/H₂O (containing 0.1 % of TFA). The eluted fractions containing the desired products and with a purity >95% were collected, while the organic solvent was removed. The pH of the water solution was adjusted to 7 before lyophilizing. The purity of the new PAs was confirmed by an analytical HPLC instrument using a C₁₈ column at wavelength of 220 nm with a linear gradient of Acetonitrile (0.1% TFA) and water (0.1% TFA) from 5% to 95% for 30 min.

Self-Assembly Protocol.^{19, 21}

All PA samples were self-assembled in water at 1 mg/mL and the pH adjusted to 7. The solutions were maintained at room temperature for 24 hours before testing. Additionally, PA 4 and PA 7 were self-assembled under various conditions and MIC was determined. Aged samples were prepared 3 days before testing and were self-assembled in water at a 2 mg/mL concentration. For annealing, PAs were self-assembled in water at 2 mg/mL, heated at 80°C for 3 hours and then cooled at room temperature. For HFIP, solutions were prepared at 2 mg/mL concentration in HFIP. HFIP was evaporated and PAs were reconstituted in water and the pH was adjusted to 7. Solutions were maintained at room temperature 24 hr before testing. In order to exchange TFA with HCl the PAs were dissolved in HCl (0.1 M) and were evaporated to remove TFA and then lyophilized. Solutions were prepared at 2 mg/mL, the pH was adjusted to 7, and solutions were maintained at room temperature for 24 hours before testing.

Circular Dichroism (CD).^{19, 21}

The PAs were dissolved in MMilli-Q water (Milli-Q Integral water purification system, Billerica, MA) to 2 mM at pH 7. CD studies were done in a J-815 Jasco Circular Dichroism Spectrometer (Easton, MD) with a 0.1 mm quartz cuvette at 25 °C. The wavelengths were set at 190–300 nm with a scan speed of 100 nm/min. The response time was set at 2 sec, and the bandwidth was set to 1 nm. The water was used as a reference (blank) and five scans were recorded for each PA.

Transmission Electron Microscopy (TEM) Imaging.^{20, 21}

The PAs were dissolved in ultrapure water to give a final concentration of 2 mM and aged for 24 hr before the experiments. Approximately 10 µL of sample was applied into a copper grid and allowed to absorb for 2–5 min, covered with a folded piece of filter paper like a tent. The excess PA was removed from the grid by inverting the forceps and touching only the edge of the grid to a clean piece of filter paper. Then, 1 drop of the negative stain (NanoVan) was added for 2 min. The excess stain was blotted off as before, and the PA was visualized at several magnifications.

Antibacterial Assay.²²

Staphylococcus aureus USA 300 JE2, *Staphylococcus aureus* USA300 LAC, *Escherichia coli* K12 were provided by Dr. Bayles' research lab and *Pseudomonas aeruginosa* PA01 was provided by Dr. Gus Wang's lab (both at the Department of Pathology and Microbiology of the University of Nebraska Medical Center – UNMC). The MICs of the PAs were studied using the broth microdilution method. Bacterial cultures were made by the direct colony

suspension method to 1.5×10^8 colony forming unit CFU/ml and dilute for 2 mL into 40 mL of Muller Hinton Broth (MHB) to a final concentration of $\sim 10^5$ CFU/mL. A stock solution of each PAs was prepared in ultrapure water at 1 mg/ml concentration and pH was adjusted to 7. Then, serial dilutions were made in MHB, in Cellstar 96-well microtiter plates (Greiner, Bio-One). Each well was inoculated with 10 μ L of bacterial cultures. The plates were incubated statically for 16–24 h at 37°C. The lowest concentration of PA that prevented bacterial growth was considered the MIC. The O.D value was set at 600 nm and was recorded with an AccuSkan, MultiSkan FC (Thermo Fisher Scientific). Vancomycin and Gentamicin were used as positive controls and media was used as negative control. The assay was performed in triplicate.

Isothermal Titration Microcalorimetry (ITC).

E. coli ATCC 29425 and *S. aureus* ATCC 25923 were used for ITC experiments. The calorimetric measurements were conducted on a TAM III microcalorimetric system with a stainless-steel sample cell (1 mL volume) at 298.15 ± 0.01 K. The reference cell was filled with 765 μ L of buffer and the sample cell was initially loaded with 600 μ L bacteria solution at 1.5×10^8 CFU/mL, and then the PAs were injected into the sample cell (10 μ L) per injection via a Hamilton syringe (500 μ L) using a 612 Thermometric Lund pump until the addition was completed. Solutions of PA 4 and PA 7 at 25 μ g/mL for titration into *E. coli* and *S aureus*; PA 12 at 180 μ g/mL for titration into *E. coli* and 45 μ g/mL for titration into *S aureus*; and PA 15 at 500 μ g/mL for titration into *E. coli* and 170 μ g/mL for titration into *S aureus*. The interval between two injections (12 minutes) was long enough to reach equilibrium. The solution in the sample cell was stirred at 90 rpm with a gold propeller. The ITC curves were fitted with NanoAnalyze software in an ITC package (supplied by TA Instruments Inc.).

Scanning Electron Microscopy (SEM) Characterization:

E. coli K12 and *S. aureus* JE2 USA 300 (MRSA) bacterial strain were grown in Muller Hinton Broth and incubated at 37°C. The resultant mid-log phase cultures were diluted to a final concentration of 1.5×10^8 CFU/mL (0.5 McFarland). The bacteria were treated with PAs at twice the MIC value and incubated for 1 h at 37°C. A control was prepared with no PA added. After PA addition, the bacteria were washed three times with HyClone™ Dulbecco's Phosphate Buffered Saline solution (GE Healthcare Life Science) and the samples fixed with 2.0% (v/v) glutaraldehyde and 2% (v/v) of paraformaldehyde in phosphate buffer (0.1 M). Samples for SEM imaging were fixed by immersion in a solution of 2% glutaraldehyde, 2% paraformaldehyde in Sorenson's phosphate buffer (0.1 M, pH 6.2) for a minimum of 24 h at 4°C. Samples were then placed on glass chips coated with 0.1% Poly-L Lysine and allowed to adhere for 30 minutes. Chips were then washed three times with phosphate buffer to clear excess fixative. Samples were post-fixed in a 1% aqueous solution of osmium tetroxide for 30 minutes to aid in conductivity. Subsequently, samples were dehydrated in a graded ethanol series (50, 70, 90, 95, 100%). Following dehydration, samples were critical point dried and attached to aluminum SEM stubs with double-sided carbon tape. Silver paste was applied to increase conductivity. The following day, samples were coated with ~ 50 nm Gold-Palladium alloy in a Hummer VI Sputter Coater (Anatech USA) and imaged at 30kV in a FEI Quanta 200 SEM operating in high vacuum mode.

Live/Dead Assay for Bacterial Cultures.

S. aureus JE2 USA 300 was grown to the mid log phase in MHB at 37°C under constant shaking at 150 rpm, washed twice and diluted to a concentration of 10⁶ CFU/mL in a saline solution (0.85%). The bacteria were treated with **PA 2**, **PA 5** and **PA 10** at their MIC values and a fixed Propidium Iodide (PI) concentration of 10 µg/mL for 30 minutes at 37°C. The cells were immediately washed and resuspended in saline 0.85%. As control we used cultures with PI, no PI and treated with EtOH 70%. Readings were obtained with a flow cytometry at a wavelength of 488 nm (excitation).

Confocal Laser Scanning Microscopy.

S. aureus JE2 USA 300 was grown to the mid log phase in MHB at 37°C under shaking at 150 rpm, washed twice, centrifuged for 5 min at 2000g, and diluted to 1 × 10⁸ CFU/mL in PBS. The bacteria were incubated with **PA 2**, **PA 3**, **PA 5** and **PA 10** at twice MIC values for 60 minutes at 37°C. Cells were washed with PBS, and incubated in dark with PI (10 µg/mL final concentration) for 15 min at 37°C. Immediately the cells were washed and re-suspended in PBS. Slides were prepared using antifade reagent with DAPI. Untreated control without the addition of PAs (negative control) and EtOH 70% (positive control) were performed following the exact same procedure for the treated samples. Images were captured using a confocal laser-scanning microscope (Zeiss 710) and the data were analyzed using Zen 2010 software.

Inner Membrane Permeabilization Assay.

Inner membrane permeabilization was determined by measuring the *L*-galactosidase release into the medium using *o*-Nitrophenyl-β-D-galactopyranoside (ONPG) as a substrate.²³ *E. coli* K12 was grown (logarithmic phase) in LB medium supplemented with 2% lactose, washed and resuspended in PBS to 10⁶ CFU/ml. Bacterial suspension (90 µL) was added into each well of a 96-well followed by 10 µL ONPG S(30 mM) and serial dilutions of PAs (100 µL) in PBS. Polymyxin B (PMB), a potent membrane-active peptide, was used as a reference compound. The *o*-nitrophenol was quantified by measuring absorbance at 415 nm at various time intervals at 37°C. Wells containing bacteria suspension, ONPG and PBS were used as control. The experiment was performed in triplicate.²⁴

Cytotoxicity assay.²²

Immortalized Human Keratinocyte (HaCaT) cell line was donated by Dr. David Oupicky Lab (Center for Drug Delivery and Nanomedicine – UNMC) and Immortalized Human Colon Epithelial Cell (HCEC) line was donated by Dr. Robert Lewis Lab (Eppley Cancer Institute – UNMC). The HaCaT cells were cultured in DMEM – high glucose, with 10% fetal bovine serum, and 1% penicillin/streptomycin. HCEC cells were cultured in DMEM – high glucose without sodium bicarbonate and sodium pyruvate, with Medium 199 (Invitrogen), Cosmic Calf Serum, Hydrocortisone, Sodium Selenite, Apo-Transferrin bovine, Insulin, Gentamicin, and Recombinant human EGF. The assays were carried out in sterile 96-well flat-bottomed polystyrene microtiter plates. Plates contained 100 µL of a cell suspension in each well (5000 cells/well) and were pre-incubated for 24 hours at 37 °C in a humidified environment with 5% CO₂. The samples to be tested were 2-fold diluted and 10

μL of each concentration were added to test plates in triplicate to get final concentrations ranging from 150 to 4,68 $\mu\text{g}/\text{mL}$. The test plate containing the compounds and the control (cells in culture medium) was incubated for 24 h. The plates were further incubated with 50 μL MTT solution (0.5 mg/ml) at 37 °C for 2 hrs. The top medium was then removed and 100 μL DMSO was added to each well to dissolve the formazan crystals.²⁵ The absorbance of the solution was determined at 600 nm using a multi-well plate reader AccuSkan, MultiSkan FC (Thermo Fisher Scientific).

***In Vivo* Antibacterial Studies.**

Galleria mellonella were purchased from Knutson's live bait (Michigan, USA) and maintained on wood chips in the dark until used. The experiments were performed according to the protocol of Ramarao *et al* 2012.²⁶ Briefly, larvae (2–3 cm long and 200–300 mg) were selected 24 hr before infection and placed into an empty petri dish. For a lethal dose, 1.5×10^8 CFU/mL was used for *S. aureus* JE2 USA 300. Bacterial culture were centrifuged (5000 xg for 5 min), washed twice and re-suspended in PBS buffer. 10 μL of bacteria suspension were injected on the first right proleg of the larvae using a microsyringe (LS, Innovative Labor system). After 2 hr, stock solutions of **PA 2** and **PA 5** were diluted in PBS to 300 $\mu\text{g}/\text{mL}$ and 10 μL of solutions (to obtain 15 mg/kg body weight) and were injected into different prolegs and incubated at 37°C. Insects were observed for the production of pigmentation and time of death was monitored over 96 hours. Larvae unresponsive to touch and showing the black pigmentation were considered dead. All tests in *G. mellonella* were performed in triplicate (n=10 larvae per each replicate). As a control, we used *G. mellonella* infected but untreated (no drug), or injected with 30 % DMSO in PBS. For statistical testing, survival data were analyzed using the Kaplan-Meier method. All statistical analyses were performed using Sigma Plot, version 5.04 (Systat Software Inc. (SSI), in San Jose, California, USA).

3. Results and discussion

PA Design and Characterization

All PAs were synthesized by standard Fmoc Solid-Phase Peptide Synthesis (SPPS), using rink amide resin, and their identity was confirmed by mass spectroscopy as described in the Experimental Section. The PA sequences and the physicochemical and morphological characteristics are listed in Table 1. The structures, morphological characteristics and purities of the PAs are shown on the SI (Figures S1–S3, Table S1).

PAs lacking amino acids that favored β -sheet interactions self-assembled into micelles (**PA 1–5**, **PA 7–8**, **PA 10–12**, and **PA 18**). Meanwhile, PAs that displayed strong intermolecular H-bonds formed nanofibers (**PA 9**, **PA 15** and **PA 17**) (Table S1). The transmission electron (TEM) micrographs of some selected PAs are shown in Figure 1 (the remaining TEM micrographs can be found on the SI **S4**). **PA 13** ($\text{C}_{10}\text{F}_4\text{K}_5$) and **PA 14** ($\text{C}_{16}\text{F}_3\text{K}_5$) formed twisted ribbons due to π - π stacking as shown by Pashuck *et al* (2010).²⁷ A previous report by Stupp and associates demonstrated that PAs containing Valine (V) and Glutamic acid (E) dimer sequences of various lengths also lead to twisted ribbons.²⁸ They showed that flat β -sheet nanostructures tend to twist because the length of the peptide sequence suppresses

lateral growth favoring the transformation to cylindrical morphology. Thus, as expected **PA 16**, with sequence C₁₆(VK)₄, presented that morphology.

The secondary structure of the PAs was assessed using Circular Dichroism (CD) (SI S3). Fiber-like assemblies, **PA 9** and **PA 13–17**, exhibited a characteristic β -sheet CD signal with negative bands \sim 218 nm and positive bands \sim 196 nm. Meanwhile, micelle-forming structures showed the expected random coil signal.¹⁶ Hydrodynamic sizes of the micelles were evaluated by dynamic light scattering using a Zetasizer Nano ZS (Malvern Instruments) at 25°C. The **PA 1**, **PA 4**, **PA 7** and **PA 12** presented hydrodynamic radii of \sim 190 nm, 166 nm, 137 nm and 99 nm, respectively (the particle size distribution can be found in the SI S5).

Antimicrobial Activity

The antimicrobial activity of the PAs was evaluated against bacteria, as well as the fungi *Candida albicans* and *Cryptococcus neoformans* (Table 2). To our surprise, neither the nanofibers nor the twisted ribbons possessed significant activity against the bacteria at 32 μ g/mL regardless of their positive charge. Additionally, the micelle forming **PA 1** (C₁₂K₅) did not show antimicrobial activity against the tested microorganisms. However, increasing the hydrophobic tail length of the **PAs**: C₁₄K₅, C₁₆K₅, C₁₈K₅ and C₂₀K₅ lead to potent and broad-spectrum antimicrobials *in vitro*. **PA 4** was effective against MRSA, *E. coli* and *C. neoformans* with a minimal inhibitory concentration (MIC) of 1 μ g/mL. **PA 4** was also active against *P. aeruginosa* (MIC = 4 μ g/mL) and *K. pneumoniae* (MIC = 16 μ g/mL). **PA 5** showed potent activity against Gram-positive bacteria and fungi with MIC of 1 μ g/mL, 4 μ g/mL and \leq 0.25 μ g/mL against MRSA, *C. albicans* and *C. neoformans*, respectively. However, it did not possess significant activity against Gram-negative bacteria. These results indicate that, in addition to supramolecular shape, the length of the alkyl tail plays an important role in antimicrobial activity. This can be seen in Table 1, with the antimicrobials **PA 2–5** (logP = 2.81, 3.70, 4.58, 5.47, respectively) being more hydrophobic than the inactive **PA 1** (logP = 1.93). We believe this relates to the ease of insertion within the bacteria membrane;¹³ however, antimicrobial activity linked to an optimal hydrophilic lipid ratio should not be discarded.

The “reversed” **PA 7** (C₁₈K-K₅) with intermediate hydrophobicity (**PA 5** >> **PA 7** >> **PA 4**) and spherical morphology was effective against MRSA (MIC = 1 μ g/mL), *E. coli* and *P. aeruginosa* (MIC = 8 μ g/mL), *C. albicans* (MIC = 2 μ g/mL), and *C. neoformans* (\leq 0.25 μ g/mL). Given this compound showed equal or lower potency than **PA 4** against the tested bacteria, but a higher Zeta potential, we theorize that the lipophilic ratio may be more important for activity than the charge of the system. Changes in the hydrophobic tail, as can be seen in **PA 8–10**, resulted in lower activity, indicating that the presence of two alkyl chains or an aromatic chain did not result in antibacterial effect.¹³ The octadecanoyl analogue **PA 11** (C₁₈O₅) was active against MRSA (MIC = 1 μ g/mL), *E. coli* (MIC = 2 μ g/mL), *P. aeruginosa* (MIC = 4 μ g/mL), *C. albicans* (MIC = 4 μ g/mL), and *C. neoformans* (\leq 0.25 μ g/mL), slightly less active than **PA 4**. This may be related to the projection of positive charges from the peptide core (ornithine has one less methylene unit than lysine), which may affect the electrostatic interactions with the membranes. Perhaps the most perplexing results

were seen with the arginine-PA **12**, which was inactive against most of the pathogens. Arginine-based PAs had been described as an effective antibacterial agent²⁹ that are able to kill pathogens at low MBC.³⁰ For example, the lipopeptide C₁₄R₃ was reported as anti-staphylococcal with anti-biofilm activity against various resistant strains of *S. aureus* equivalent to that of daptomycin and vancomycin.³¹ However, the compound was not effective against *P. aeruginosa* and *K. pneumoniae*. The pKa values of lysine and arginine (~10.5 and ~12.8, respectively) suggest a positive charge at physiological pH, which is an essential characteristic for damaging membranes. However, molecular dynamics models demonstrated that arginine is the only amino acid residue that remains protonated inside the membranes.³² Thus, the data again suggest that overall hydrophobicity (**PA 4** > **PA 12**) plays a more significant role in the antimicrobial activity than charge.

The order of hydrophobicity for PAs with active systems showing in bold is PA 9 > PA 14 > PA 17 > PA 15 > **PA 5** > PA 16 > **PA 7** > **PA 18** > PA 13 > **PA 4** > **PA 11** > **PA 3** > PA 6 > PA 2 > PA 8 > PA 1 > PA 12 > PA 10, which suggests a hydrophobic range for activity. Intriguingly, the only two inactive PAs (**PA 16** and **PA 13**) inside this range self-assemble into twisted ribbons, validating our observation of shape-dependent activity. In addition, the most effective PAs presented Zeta potential greater than + 31.46 mV and all the inactive PAs with high zeta values or > + 10 mV are either nanofibers or very hydrophobic/hydrophilic. Nanoparticles with zeta potential greater than +30 mV are considered cationic while values between - 10 mV and + 10 mV are approximately neutral.³³ Positively charged nanoparticle are associated with cell membrane disruption and cytotoxicity, due to the fact that bacteria membranes are slightly negative.^{18, 33, 34} Thus, despite shape appearing to be the main driver of antibacterial activity, the relative potency of the supramolecular structures is strongly dependent on other factors such as charge and hydrophobicity. This is not a surprise, because cationic charges and amphiphilic character have been identified as essential characteristics of AMPs.^{12, 1335}

A recent investigation by Liang and co-workers has shown that antibacterial nanoparticles possess structure-dependent activity, supporting our observations.¹² Further, Zoe *et al*³⁶ has found that positively charged micelles target the negatively charged outer membrane of *E. coli* by electrostatic interactions destroying the cellular barrier function. The micelles then disintegrate the cell's inner membrane through hydrophobic interactions between the hydrophobic tails of the PAs and the lipid component of the bacterial membrane, and these interactions lead to subsequent cytoplasmic leakage and cell death.³⁶

In order to evaluate the effect of sample processing on antimicrobial activity, **PA 4** and **PA 7** were self-assembled under different conditions: *i*) aging for 3 days, *ii*) annealing, *iii*) using hexafluoroisopropanol (HFIP) to dissolve PA aggregates before assembly in water, *iv*) by exchanging the counter ion (TFA/HCl). The samples were tested against MRSA and *E. coli* K12 with no observed changes in antimicrobial activity (SI Table S2).

The minimum bactericidal concentration (MBC), dosage at which > 99.9% bacteria are killed, was determined for selected PAs against MRSA and *E. coli*. The MBC is reduced sharply from **PA 12** to **PA 4** against MRSA. **PA 4** showed MBC at 16 µg/mL, corresponding to two-fold more than MIC while **PA 12** did not show MBC up to 256 µg/mL. Similar

results were obtained against *E. coli*, **PA 4** and **PA 12** killed > 99.9% bacteria at 8 µg/mL and 128 µg/mL, respectively. Thus, lysine-based PAs were more effective at killing MRSA and *E. coli* than arginine-based PAs.

Biofilm formation, a virulence factor associated with many bacterial infections, can significantly increase bacterial resistance to antibiotics. AMPs have shown potent anti-biofilm activity against multi-drug resistant bacteria strains at low concentrations and synergism with antibiotics.³⁷ We investigated the efficacy of **PA 4** micelles to inhibit the production of MRSA and *E. coli* biofilms using a crystal violet staining assay.³⁸ For the biofilm formation inhibition assays, initial *S. aureus* JE2 and *E. coli* K12 inoculums were added in two-fold dilutions with concentration ranging from 16 to 4 µg/mL and 4 to 1 µg/mL for **PA 4** and vancomycin or gentamicin, respectively. **PA 4** reduced MRSA biofilm formation up to 68.80 ± 3.62 % at MIC while Vancomycin caused a reduction up to 92.80 ± 0.68 % (SI S6). At $2 \times$ MIC, **PA 4** was able to inhibit the adhesion of biofilms causing more than 90% reduction. **PA 4** was less effective at inhibiting *E. coli* biofilms. **PA 4** did not reduce biofilms formation up to 16 µg/mL, which corresponds to $4 \times$ MIC and caused a reduction of 39.5% at 32 µg/mL while Gentamicin caused a reduction of about 54.3% at 2 µg/mL (SI S6).

Isothermal Titration Calorimetry (ITC)

We used isothermal titration calorimetry (ITC) to observe thermodynamic changes in the binding process of PA micelles and nanofibers to *S. aureus* and *E. coli*. Figure 2 shows the variation of observed enthalpy (ΔH_{obs}) when PAs were titrated into *S. aureus* and *E. coli* solutions. The ITC curves show that micelles (**PA 4**, **PA 7** and **PA 12**) possess a strong binding affinity with bacteria membranes, demonstrating exothermic values. With the addition of PAs, the ΔH_{obs} values changed from larger exothermic to zero, reaching the saturation of interaction of the PAs with *S. aureus* membrane. The same result was observed for *E. coli*. However, a nanofiber (**PA 15**) showed a weak binding affinity with the bacterial membranes, displaying a line with small curvature. The electrostatic binding of positively charged PAs with negatively charged bacteria was highly associated with the observed exothermic effect. **PA 4** and **PA 7** (zeta potential values of 31.46 ± 1.75 and 45.43 ± 2.58 mV, respectively) show greater negative enthalpy change values to both *S. aureus* and *E. coli*. **PA 12** (zeta potential value of 14.10 ± 1.21 mV) has a weak exothermic effect in *E. coli*, but it has a strong exothermic effect with *S. aureus*, indicating that the arginine group has stronger affinity with *S. aureus*. **PA 15** (zeta potential value of 16.56 ± 2.55 mV) has the weakest interaction enthalpy values with *S. aureus* and *E. coli*.

The ITC curves were analyzed by independent binding model as described in the SI. The binding constant (K_b) of PA decreased in the following order: $K_{\text{PA}2} > K_{\text{PA}5} > K_{\text{PA}10} > K_{\text{PA}13}$ for *S. aureus* and $K_{\text{PA}5} > K_{\text{PA}2} > K_{\text{PA}10} > K_{\text{PA}13}$ for *E. coli*, respectively (Table 3). These results suggest that PA micelles possess better antimicrobial activity than nanofibers, because they are able to bind and interact more efficiently with the bacterial membrane. The micelle **PA 4** antibacterial activity is 8-fold more potent than nanofiber **PA 15** against *S. aureus* and 32-fold more potent against *E. coli*. Despite the impact that the hydrophobicity and cationic charge has on the biological activity of PAs, the most apparent difference in

biological activity was observed when the morphology of nanostructures was modified. Both **PA 4** (C₁₈K₅) and **PA 15** (C₁₈V₃K₅) possess the same overall charge but differ in their amino acid composition; **PA 15** contains valine, which leads to nanofibers formation. The weaker intermolecular van der Waals interactions (when compared to hydrogen bonding) make micelles less stable than nanofibers.³⁹ We hypothesize that the strength of intramolecular cohesion stabilizes the supramolecular structures and diminishes interaction with membrane. Recent studies suggest that intermolecular cohesion determines the ability of a supramolecular assembly to disrupt the membrane of cancer cells.⁴⁰

PA amphiphile micelles action on bacteria membrane:

To get visual insights into the mechanism of action of the PA micelles, the morphological changes of *S. aureus* JE2 and *E. coli* K12 exposed to micelles at 2 × MIC were observed by TEM and scanning electron microscopy (SEM). It was observed that after treatment with **PA 4** and **PA 7** membrane damage took place, with **bacterial** debris and burst bacterial membranes seen by TEM (SI S7) and SEM (Figure 3). *S. aureus* showed protruding bumps, cytoplasmic leakage and deep holes after treatment (1 hr) with PAs while *E. coli* presented deep craters and severe membrane deformations. The morphological changes indicate the PAs kill bacteria by disrupting their membranes (although other mechanism may also take place).

We further confirmed the ability of PAs to disrupt cell membrane using confocal microscopy by a double staining method with DAPI (4',6-diamidino-2-phenylindole dihydrochloride) and PI (propidium iodide), as fluorophores. DAPI binds bacterial cells irrespective of their viability by intercalating with DNA giving a bright blue fluorescent complex. However, PI only crosses damaged cell membranes, intercalating with DNA forming a bright red fluorescent complex.¹⁵ After treatment with **PA 4** and **PA 7**, cells showed PI fluorescence, suggesting that their action involves permeation of the microorganism's membrane, similar to other AMPs (Figure 4 and S8).¹⁰

The incorporation of PI in *S. aureus* and *E. coli* K12 treated with PAs was further evaluated by flow cytometry. The viability of *S. aureus* with no PA treatment was detected to be about 91%, suggesting intact bacterial cytoplasmic membranes (Figure 5). After treatment with **PA 4** and **PA 7**, the cell viability decreased to 29.1% and 12.7% respectively, indicating cell death presumably due to permeabilized membranes. **PA 4** and **PA 7** were able to kill *S. aureus* at 1 × MIC after 30 minutes of treatment. However, the inactive **PA 12** did not kill cells at 1 × MIC (Figure 5) and 2 × MIC (SI S9). The viability of *S. aureus* after treatment with **PA 12** at 1 × MIC was 92.7 %, this result is consistent with the MBC > 256 µg/mL, discussed previously.

Treating (30 min) *E. coli* with **PA 4** and **PA 7** at 1 and 2 × MIC showed 23.1%, 28.9%, 7% and 6.2 % dead cells (SI S10 –S11), respectively. As discussed previously, **PA 4** displayed MBC of 8 µg/mL against *E. coli* after 3 hours incubations. The discrepancy in these results can be related to the time of incubation and indicate that **PA 4** is able to kill *S. aureus* faster than *E. coli*. **PA 12** did not kill *E. coli* at 1 and 2 × MIC (SI S11), consistent with an MBC of 128 µg/mL.

We further evaluated the ability of selected PAs to permeate the *E. coli* inner membrane by monitoring the hydrolysis of nitrophenyl- β -D-galactopyranoside (ONPG) by cytoplasmic β -galactosidase. Because ONPG cannot traverse the inner membrane, its hydrolysis to yellow *o*-nitrophenol suggests that permeabilization of the inner membrane and β -galactosidase escape have taken place.^{23, 24} Treatment of *E. coli* with **PA 4** and **PA 7** resulted in permeabilization of the inner membrane at 16 $\mu\text{g/mL}$, which are equivalent to $4 \times$ and $2 \times$ MIC, respectively, when compared with Polymyxin B (PMB) at 0.5 $\mu\text{g/mL}$. PMB, a drug known to disrupt *E. coli*'s membrane (IM).⁴¹ **PA 12** did not produce permeabilization of the inner membrane at 32 $\mu\text{g/mL}$.

These results confirm that PAs micelles disrupt bacterial membrane more efficiently than nanofibers, killing bacteria with a mechanism of action associated with membrane disruption. A recent report has shown that the cellular internalization is strongly dependent on micelles' stability.⁴² The more stable micellar structures enter cells by endocytosis disassembling inside while less stable micelles can intercalate into the membrane as monomers penetrating cells directly.⁴² Our current hypothesis is that the less stable micelles (when compared to nanofibers) work as a monomer reservoir; they disassemble leading to lipophilic tail intercalation into the membrane and subsequent bacterial death⁴³ (Figure 7). Note the mechanism of action for Daptomycin involves disruption of the bacterial cell membrane by the insertion of a lipophilic chain into this barrier. This permits the flow of potassium ions out of the cell causing depolarisation, and consequently resulting in cell death. In addition, a study has revealed that this lipopeptide can self-assemble into spherical micelles raising the possibility of disruption of the cell membrane when it is disassembled at the bacterial membrane.⁴³

Cytotoxicity and Hemolytic Activity

The cytotoxicity of the active PAs against immortalized human keratinocyte (HaCaT) and immortalized human colonic epithelial (HCEC) cells was assessed using the the MTT assay. In addition, we studied cell viability of human embryonic kidney cells (ATCC CRL-1573) using resazurin. The IC_{50} of selected systems was determined from the dose response curves of each PA. The hemolytic activity of active PAs was determined against human red blood cells and the HC_{10} and HC_{50} values (concentration at 10% and 50% haemolysis, respectively) calculated by curve fitting of the inhibition values vs. $\log(\text{concentration})$ are summarized in the table 4.

Most of PAs showed IC_{50} values $>32 \mu\text{g/mL}$ against HaCaT and HEK-293, except **PA 5** and **PA 11**, which displayed toxicity against HEK-293 cells at 20.8 and 20.3 $\mu\text{g/mL}$ respectively (Table 4). The PAs were found to be more toxic against HCEC; all of which showed values $< 32 \mu\text{g/mL}$ (except for **PA 12**). Also, **PA 12** and **PA 13** showed hemolytic activity with $\text{HC}_{50} < 32 \mu\text{g/mL}$. As discussed previously, **PA 1** (C_{12}K_5), **PA 4** (C_{18}K_5) and **PA 5** (C_{20}K_5) presented the same amino acid sequence with differing hydrophobic tail lengths. The **PA 1** did not show antibacterial activity against the strains tested and did not show toxicity against HEK-293 cells and human red blood cells. **PA 4** and **PA 5** present similar antimicrobial activity but **PA 5** exhibited lower IC_{50} values against mammalian cells. The hydrophobic tail and cationic charge are essential characteristics for antibacterial activity, but they also

influence the cell viability; as lipophilicity increases, the hemolytic activity of the PAs also increases, compromising the selectivity of PAs. Shortening the tail length to 12 carbons resulted in a nontoxic PA but no antimicrobial activity. Other studies have reported a similar observation reducing the amphiphilic nature of the assemblies by decreasing the alkyl tail enhances cell viability.⁴⁰ We expected that **PA 2** (C₁₄K₅) and **PA 3** (C₁₆K₅) would be less toxic for mammalian and red blood cells than **PA 4**, but the obtained data did not support our assumption. More studies need to be performed to find a proper balance of charge and hydrophobicity in order to design more selective PAs (Cytotoxicity/MIC).

***In vivo* studies**

Galleria mellonella (wax moth larvae) has become a viable alternative to other animal models for the preliminary study of pathogenic bacteria. The wax moth larvae's immune system shares structural and functional similarity to the vertebrate's innate immune system.⁴⁴ Furthermore, larvae are more cost-effective to establish, easier to maintain when compared with traditional mammalian model hosts, and they do not require ethical approval.⁴⁵

First, we evaluated the toxicity of **PA 4** and **PA 7** at 30 mg/kg and 60 mg/kg towards the *G. mellonella* larvae (Figure 8 A). We found the PAs did not affect larval survival when compared with the PBS-treated control, and, therefore, they were deemed to be nontoxic at these doses. The effect of single doses of **PA 4** and **PA 7** (60 mg/kg body weight) 2 hours post infection with *S. aureus* JE2 MRSA (inoculum 3×10^8 CFU/mL) on the survival of *G. mellonella* larvae are shown in Figure 8 B and SI 12. Infected larvae treated with **PA 4** and **PA 7** showed a greater percentage of survival up to 48 hours when compared with untreated larvae, although a decrease was observed after the 48 hours. Experiments were performed to evaluate the efficacy of multiple doses, 2 hr post infection and 12 hr post first dose. Increase in survival was not observed when compared to a single dose effect (data not shown), which may be due to larvae trauma after multiple injections or metabolism of the PAs.

4. Conclusion

We have designed cationic PAs that self-assemble into supramolecular nanostructures such as micelles, nanofibers, and twisted ribbons. The micelles exhibited promising antimicrobial activity against a panel of Gram-positive and Gram-negative bacteria, as well as fungi with a mechanism of action associated with membrane damage. The results suggest that antibacterial activity is shape-dependent, related to hydrophobicity, and, to a lesser extent, Zeta potential. We hypothesize that intramolecular cohesion determines the antimicrobial activity because micelles are less stable than nanofibers, they may easily disassemble and insert in the bacteria membrane causing cell death. Thus, we believe the micelles work as a monomer reservoir. More studies are needed to find the proper balance between cationic charge and hydrophobicity to achieve efficient antimicrobial action, with low hemolytic activity and toxicity against mammalian cells. PAs micelles provide a great opportunity to develop new therapies in combination with other drugs to achieve synergistic antibacterial action as seen with other membrane disruptors such as pentamidine.^{46, 47}

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by Start-up funds and NIH-COBRE (5P20GM103480- Nebraska Center for Nanomedicine). We would like to thank Mohamed A. Seleem and H. Andy Zhong in the Department of Chemistry at University of Nebraska Omaha for the logP calculations in MOE software. We thank the CO-ADD (The Community for Antimicrobial Drug Discovery), funded by the Wellcome Trust (UK), at The University of Queensland (Australia) for doing antimicrobial tests against bacteria and fungi, cytotoxicity against HEC-293, and hemolytic assays in Human red blood cells. We would also like to express our gratitude to the Advanced Microscopy Core Facility at UNMC (Janice A. Taylor and James R. Talaska) confocal microscopy and the Flow Cytometry Research Facility at UNMC (Samantha Wall) for providing experimental assistance. The authors would like thank to Mehdi Bin Samad for providing some of the TEM images, and of the Electron Microscopy Core Facility (EMCF) at UNMC (Tom Bargar and Nicholas Conoan) for assistance. The EMCF is supported by the Nebraska Research Initiative (NRI) and the University of Nebraska Foundation, and the Office of the Vice Chancellor for Research.

Abbreviations used

5.

PAs	Peptide amphiphiles
MRSA	methicillin-resistant <i>S. aureus</i>
AMPs	Antimicrobial peptides
HPLC	High Performance Liquid Chromatography
TEM	Transmission Electron Microscopy
ITC	Isothermal Titration Calorimetry
CFU	colony forming units
SEM	Scanning electron microscopy
CD	Circular Dichroism
MIC	minimal inhibitory concentration
MBC	minimum bactericidal concentration
ATCC	American Type Culture Collection

8. References

1. Alekshun MN; Levy SB Molecular Mechanisms of Antibacterial Multidrug Resistance. *Cell* 2007, 128, 1037–1050. [PubMed: 17382878]
2. Blair JM; Webber MA; Baylay AJ; Ogbolu DO; Piddock LJ Molecular Mechanisms of Antibiotic Resistance. *Nat. Rev. Microbiol* 2015, 13, 42. [PubMed: 25435309]
3. CDC. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States; United States, 2013; p 114.
4. Taubes G The Bacteria Fight Back Science (Washington, DC, U. S.) 2008, 321, 356–361. [PubMed: 18635788]

5. Li J; Koh J-J; Liu S; Lakshminarayanan R; Verma CS; Beuerman RW Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design. *Front. Neurosci.*-Switz 2017, 11, 73.
6. Tenover FC Mechanisms of Antimicrobial Resistance in Bacteria. *Am. J. Infect. Control* 2006, 34, S3–S10. [PubMed: 16813980]
7. Odonkor ST; Addo KK Bacteria Resistance to Antibiotics: Recent Trends and Challenges. *Int. J. Biol. Med. Res* 2011, 2, 1204–1210.
8. Bush K; Courvalin P; Dantas G; Davies J; Eisenstein B; Huovinen P; Jacoby GA; Kishony R; Kreiswirth BN; Kutter E Tackling Antibiotic Resistance. *Nat. Rev. Microbiol* 2011, 9, 894. [PubMed: 22048738]
9. Shankar SS; Benke SN; Nagendra N; Srivastava PL; Thulasiram HV; Gopi HN Self-Assembly to Function: Design, Synthesis, and Broad Spectrum Antimicrobial Properties of Short Hybrid E-Vinylogous Lipopeptides. *J. Med. Chem* 2013, 56, 8468–8474. [PubMed: 24117107]
10. Makovitzki A; Baram J; Shai Y Antimicrobial Lipopolypeptides Composed of Palmitoyl Di-and Tricationic Peptides: In Vitro and In Vivo Activities, Self-Assembly to Nanostructures, and a Plausible Mode of Action. *Biochemistry* 2008, 47, 10630–10636. [PubMed: 18783248]
11. Wimley WC Describing the Mechanism of Antimicrobial Peptide Action with the Interfacial Activity Model. *ACS Chem. Biol* 2010, 5, 905–917. [PubMed: 20698568]
12. Jiang Y; Zheng W; Kuang L; Ma H; Liang H Hydrophilic phage-mimicking membrane active antimicrobials reveal nanostructure-dependent activity and selectivity. *ACS Infect. Dis* 2017, 3, 676–687. [PubMed: 28758395]
13. Ma Z; Yang J; Han J; Gao L; Liu H; Lu Z; Zhao H; Bie X Insights Into the Antimicrobial Activity and Cytotoxicity of Engineered α -Helical Peptide Amphiphiles. *J. Med. Chem* 2016, 59, 10946–10962. [PubMed: 28002968]
14. Ong ZY; Gao SJ; Yang YY Short Synthetic β -Sheet Forming Peptide Amphiphiles as Broad Spectrum Antimicrobials with Antibiofilm and Endotoxin Neutralizing Capabilities. *Adv. Funct. Mater* 2013, 23, 3682–3692.
15. Niu Y; Padhee S; Wu H; Bai G; Qiao Q; Hu Y; Harrington L; Burda WN; Shaw LN; Cao C Lipoy-AApeptides as a New Class of Potent and Broad-Spectrum Antimicrobial Agents. *J. Med. Chem* 2012, 55, 4003–4009. [PubMed: 22475244]
16. Dehsorkhi A; Castelletto V; Hamley IW Self-Assembling Amphiphilic Peptides. *J. Pep. Sci* 2014, 20, 453–467.
17. Fan T; Yu X; Shen B; Sun L Peptide Self-Assembled Nanostructures for Drug Delivery Applications. *J. Nanomater* 2017, 2017.
18. Liu L; Xu K; Wang H; Tan PJ; Fan W; Venkatraman SS; Li L; Yang Y-Y Self-Assembled Cationic Peptide Nanoparticles as an Efficient Antimicrobial Agent. *Nat. Nanotechnol* 2009, 4, 457. [PubMed: 19581900]
19. Conda-Sheridan M; Lee SS; Preslar AT; Stupp SI Esterase-Activated Release of Naproxen from Supramolecular Nanofibres. *Chem. Commun* 2014, 50, 13757–13760.
20. Samad MB; Maddeboina K; Rodrigues de Almeida N; Conda-Sheridan M Facile Protocol for the Synthesis of Self-Assembling Polyamine-based Peptide Amphiphiles (PPAs) and Related Biomaterials. *J. Vis. Exp* 2018.
21. Samad MB; Chhonker YS; Contreras JI; McCarthy A; McClanahan MM; Murry DJ; Conda-Sheridan M Developing Polyamine-Based Peptide Amphiphiles with Tunable Morphology and Physicochemical Properties. *Macromol. Biosci* 2017, 17.
22. Krishnaiah M; de Almeida NR; Udumula V; Song Z; Chhonker YS; Abdelmoaty MM; do Nascimento VA; Murry DJ; Conda-Sheridan M Synthesis, Biological Evaluation, and Metabolic Stability of Phenazine Derivatives as Antibacterial Agents. *Eur. J. Med. Chem* 2018, 143, 936–947. [PubMed: 29227933]
23. Balakrishna R; Wood SJ; Nguyen TB; Miller KA; Kumar ES; Datta A; David SA Structural Correlates of Antibacterial and Membrane-Permeabilizing Activities in Acylpolyamines. *Antimicrob. Agents Ch* 2006, 50, 852–861.
24. Ibrahim HR; Sugimoto Y; Aoki T Ovotransferrin Antimicrobial Peptide (OTAP-92) Kills Bacteria Through a Membrane Damage Mechanism. *BBA-Gen. Subjects* 2000, 1523, 196–205.

25. Xu M; McCanna DJ; Sivak JG Use of the Viability Reagent PrestoBlue in Comparison with AlamarBlue and MTT to Assess the Viability of Human Corneal Epithelial Cells. *J. Pharmacol. Tox. Met* 2015, 71, 1–7.
26. Ramarao N; Nielsen-Leroux C; Lereclus D The Insect *Galleria Mellonella* as a Powerful Infection Model to Investigate Bacterial Pathogenesis. *J. Vis. Exp* 2012, e4392. [PubMed: 23271509]
27. Pashuck ET; Stupp SI Direct Observation of Morphological Transformation from Twisted Ribbons into Helical Ribbons. *J. Am. Chem. Soc* 2010, 132, 8819–8821. [PubMed: 20552966]
28. Moyer TJ; Cui H; Stupp SI Tuning Nanostructure Dimensions with Supramolecular Twisting. *J. Phys. Chem. B* 2012, 117, 4604–4610. [PubMed: 23145959]
29. Chan DI; Prenner EJ; Vogel HJ Tryptophan- and Arginine-Rich Antimicrobial Peptides: Structures and Mechanisms of Action. *BBA-Biomembranes* 2006, 1758, 1184–1202. [PubMed: 16756942]
30. Mi G; Shi D; Herchek W; Webster TJ Self-Assembled Arginine-Rich Peptides as Effective Antimicrobial Agents. *J. Biomed. Mater. Res. A* 2017, 105, 1046–1054. [PubMed: 27977886]
31. Mishra B; Lushnikova T; Wang G Small Lipopeptides Possess Anti-Biofilm Capability Comparable to Daptomycin and Vancomycin. *RSC Adv.* 2015, 5, 59758–59769. [PubMed: 26257894]
32. Li L; Vorobyov I; Allen TW The Different Interactions of Lysine and Arginine Side Chains with Lipid Membranes. *J. Phys. Chem. B* 2013, 117, 11906–11920. [PubMed: 24007457]
33. Clogston JD; Patri AK Zeta Potential Measurement Characterization of Nanoparticles Intended for Drug Delivery; 1rd ed; Humana Press, 2011, pp 63–70. In Springer.
34. Wang H; Xu K; Liu L; Tan JP; Chen Y; Li Y; Fan W; Wei Z; Sheng J; Yang Y-Y The Efficacy of Self-Assembled Cationic Antimicrobial Peptide Nanoparticles Against *Cryptococcus Neoformans* for the Treatment of Meningitis. *Biomaterials* 2010, 31, 2874–2881. [PubMed: 20044131]
35. Travkova OG; Moehwald H; Brezesinski G The Interaction of Antimicrobial Peptides with Membranes. *Adv. Colloid Interfac* 2017, 247, 521–532.
36. Zhou C; Wang F; Chen H; Li M; Qiao F; Liu Z; Hou Y; Wu C; Fan Y; Liu L Selective Antimicrobial Activities and Action Mechanism of Micelles Self-Assembled by Cationic Oligomeric Surfactants. *ACS Appl. Mater. Inter* 2016, 8, 4242–4249.
37. Chung PY; Khanum R Antimicrobial Peptides as Potential Anti-Biofilm Agents Against Multidrug-Resistant Bacteria. *J. Microbiol. Immunol* 2017, 50, 405–410.
38. Garrison AT; Bai F; Abouelhassan Y; Paciaroni NG; Jin S; Huigens III RW Bromophenazine Derivatives with Potent Inhibition, Dispersion and Eradication Activities Against *Staphylococcus Aureus* Biofilms. *RSC Adv.* 2015, 5, 1120–1124.
39. Cui H; Webber MJ; Stupp SI Self-Assembly of Peptide Amphiphiles: From Molecules to Nanostructures to Biomaterials. *Biopolymers* 2010, 94, 1–18. [PubMed: 20091874]
40. Newcomb CJ; Sur S; Ortony JH; Lee O-S; Matson JB; Boekhoven J; Yu JM; Schatz GC; Stupp SI Cell Death Versus Cell Survival Instructed by Supramolecular Cohesion of Nanostructures. *Nat. Commun* 2014, 5, 3321. [PubMed: 24531236]
41. Kanazawa K; Sato Y; Ohki K; Okimura K; Uchida Y; Shindo M; Sakura N Contribution of Each Amino Acid Residue in Polymyxin B3 to Antimicrobial and Lipopolysaccharide Binding Activity. *Chem. Pharm. Bull* 2009, 57, 240–244. [PubMed: 19252313]
42. Feiner-Gracia N; Buzhor M; Fuentes E; Pujals S; Amir RJ; Albertazzi L Micellar Stability in Biological Media Dictates Internalization in Living Cells. *J. Am. Chem. Soc* 2017, 139, 16677–16687. [PubMed: 29076736]
43. Kirkham S; Castelletto V; Hamley IW; Inoue K; Rambo R; Reza M; Ruokolainen J Self-Assembly of the Cyclic Lipopeptide Daptomycin: Spherical Micelle Formation Does not Depend on the Presence of Calcium Chloride. *ChemPhysChem* 2016, 17, 2118–2122. [PubMed: 27043447]
44. Pereira MF; Rossi CC; de Queiroz MV; Martins GF; Isaac C; Bosse JT; Li Y; Wren BW; Terra VS; Cuccui J *Galleria Mellonella* Is an Effective Model to Study *Actinobacillus Pleuropneumoniae* Infection. *Microbiology* 2015, 161, 387–400. [PubMed: 25414045]
45. Tsai CJ-Y; Loh JMS; Proft T *Galleria Mellonella* Infection Models for the Study of Bacterial Diseases and for Antimicrobial Drug Testing. *Virulence* 2016, 7, 214–229. [PubMed: 26730990]
46. Melander RJ; Melander C The Challenge of Overcoming Antibiotic Resistance: An Adjuvant Approach? *ACS Infect. Dis* 2017, 3, 559–563. [PubMed: 28548487]

47. Stokes JM; MacNair CR; Ilyas B; French S; Côté J-P; Bouwman C; Farha MA; Sieron AO; Whitfield C; Coombes BK; Brown ED Pentamidine Sensitizes Gram-Negative Pathogens to Antibiotics and Overcomes Acquired Colistin Resistance. *Nat. Microbiol* 2017, 2, 17028. [PubMed: 28263303]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1. TEM micrographs of various PAs. Micelles (**PA 1**, **PA 4**, **PA 7** and **PA 12**), nanofibers (**PA 15** and **PA 17**) and twisted ribbons (**PA 13** and **PA 14**).




Figure 2:
Variation of observed enthalpy changes (ΔH_{obs}) in the binding process of *S. aureus* and *E. coli* bacteria membrane with micelles (PA 4, PA 7 and PA 12) and nanofibers (PA 15).




Figure 3:
SEM micrographs of *S. aureus* JE2 MRSA (up) and *E. coli* K12 (down) cells treated with PA 4 and PA 7 at 2X MIC.




Figure 4:
Confocal fluorescence microscopic images of *Sa* JE2 MRSA treated with **PA 4** and **PA 7** at twice MIC. Control was made with no PA addition.




Figure 5: Flow cytometry analysis. Cell membrane disruption of *S. aureus* JE2 MRSA treated with **PA 4** and **PA 7** at MIC was determined by an increase in fluorescent intensity of PI. Negative control - No PA; **PA 4** at 8 $\mu\text{g}/\text{mL}$; **PA 7** at 8 $\mu\text{g}/\text{mL}$ and **PA 12** at 16 $\mu\text{g}/\text{mL}$. Treatment with EtOH 70% was used as positive control and the analysis can be found on the SI.




Figure 6: *E. coli* K12 inner membrane permeabilization. PA capability for permeabilizing *E. coli* internal membrane was evaluated by using ONPG substrate and treating bacteria with **PA 4**, **PA 7** and **PA 12** at 16, 16 and 32 µg/mL, respectively. PMB at 0.5 µg/mL was used as reference drug. The wells containing no test compound were used as control.




Figure 7:
Proposed mechanism of action of PAs micelles.




Figure 8:
G. mellonella assays. Toxicity of selected PAs (A). MRSA infection of *G. mellonella* (B).

Table 1:

Physicochemical and morphological characteristics of PAs.

PAs	Sequence	Retention time ^a (min)	LogP ^b	Morphology by TEM ^c	Zeta potential (mV) ^c
PA 1	C ₁₂ K ₅	10.95	1.93	Micelles	34.66 ± 3.21
PA 2	C ₁₄ K ₅	12.49	2.81	Micelles	34.50 ± 2.10
PA 3	C ₁₆ K ₅	14.26	3.70	Micelles	39.50 ± 4.41
PA 4	C ₁₈ K ₅	15.78	4.58	Micelles	31.46 ± 1.75
PA 5	C ₂₀ K ₅	17.27	5.47	Micelles	41.43 ± 1.38
PA 6	2-Hexyldec-K ₅	12.66	3.63	Wormlike Micelles	21.83 ± 0.47
PA 7	C ₁₈ K-K ₅	16.45	4.24	Micelles	45.43 ± 2.58
PA 8	(C ₈) ₂ K-K ₅	12.36	11.51	Micelles	18.83 ± 1.69
PA 9	(C ₁₈) ₂ K-K ₅	27.78	16.92	Short Fibers	41.40 ± 1.05
PA 10	AnthraceneK-K ₅	8.60	1.27	Micelles	38.33 ± 1.77
PA 11	C ₁₈ O ₅	15.62	2.37	Micelles	39.80 ± 1.55
PA 12	C ₁₈ R ₅	9.51	3.54	Micelles	14.10 ± 1.21
PA 13	C ₁₀ F ₄ K ₅	16.29	6.02	Twisted Ribbons	40.63 ± 1.95
PA 14	C ₁₆ F ₃ K ₃	21.27	7.31	Twisted Ribbons	44.03 ± 1.25
PA 15	C ₁₈ V ₃ K ₅	18.62	6.26	Nanofibers	16.56 ± 2.55
PA 16	C ₁₆ (VK) ₄	16.84	6.28	Twisted Ribbons	40.56 ± 2.31
PA 17	C ₁₆ V ₃ A ₃ K ₃	19.15	4.83	Nanofibers	33.76 ± 0.63
PA 18	C ₁₈ K ₃ 1-peptoid	16.35	4.56	Micelles	36.26 ± 1.46

Lysine (K), Ornithine (O), Arginine (R), Phenylalanine (F), Valine (V) and Alanine (A), Caprylic acid (C8), Decanoic acid (C10), Dodecanoic acid (C12), Myristic acid (C14), Hexadecanoic acid (C16), Octadecanoic acid (C18), Eicosanoic acid (C20).

^aLinear gradient of Acetonitrile (0.1% TFA) and water (0.1% TFA) from 5% to 95% in 30 min.

^bCalculated from Molecular Operating Environment (MOE).

^cAqueous solution of 2 mmolar concentration in pH 7.

Table 2:

Antibacterial activity of the PA (Antimicrobial PAs micelles are indicated with green color).

PAs	MIC ($\mu\text{g/mL}$)										
	Gram-positive			Gram-negative					Fungi		
	<i>Sa</i> ^a	<i>Sa</i> ^b	<i>Sa</i> ^c	<i>Ec</i> ^d	<i>Ec</i> ^e	<i>Pa</i> ^f	<i>Pa</i> ^g	<i>Kp</i> ^h	<i>Ab</i> ⁱ	<i>Ca</i> ^j	<i>Cn</i> ^k
PA 1	>32	>32	>32	\geq 32	>32	>32	>32	>32	>32	>32	>32
PA 2	32	ne	8	32	16	ne	>32	>32	>32	>32	16
PA 3	16	ne	2	8	2	ne	8	32	32	32	1
PA 4	8	8	1	4	1	4	4	16	16	32	1
PA 5	16	16	1	16	8	32	>32	>32	>32	4	\leq 0.25
PA 6	16	16	>32	16	>32	>32	>32	>32	>32	>32	>32
PA 7	8	8	1	8	8	16	8	32	16	2	\leq 0.25
PA 8	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32
PA 9	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32
PA 10	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32
PA 11	8	16	1	16	2	16	4	16	16	4	\leq 0.25
PA 12	16	32	>32	\geq 32	>32	>32	>32	>32	>32	>32	16
PA 13	32	32	1	>32	8	>32	>32	>32	4	>32	0.5
PA 14	>32	>32	32	>32	>32	ne	>32	>32	>32	8	32
PA 15	>32	>32	16	>32	>32	ne	>32	>32	>32	>32	\leq 0.25
PA 16	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32
PA 17	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32
PA 18	8	8	2	16	4	ne	8	8	16	16	0.5
Van	2	2	ne	ne	ne	ne	ne	ne	ne	ne	ne
Gen	ne	ne	ne	0.25	ne	0.25	ne	ne	ne	ne	ne

^a*Staphylococcus aureus* JE2 MRSA;^b*Staphylococcus aureus* LAC MRSA;^c*Staphylococcus aureus* ATCC 43300 MRSA;^d*Escherichia coli* K12;^e*Escherichia coli* ATCC 25922;^f*Pseudomonas aeruginosa* PA01;^g*Pseudomonas aeruginosa* ATCC 27853;^h*Klebsiella pneumoniae* ATCC 700603;ⁱ*Acinetobacter baumannii* ATCC 19606;^j*Candida albicans* ATCC 90028 and^k*Cryptococcus neoformans* var. *grubii* H99 ATCC 20882. ne: not evaluated. All PAs assemblies tested were prepared in water at pH 7.

Table 3:

Thermodynamic parameters of the binding of PAs with *S. aureus* and *E. coli* K12. Binding constant (K_b) and binding number (N) derived from ITC curves. (PAs self-assembled into micelles are indicated with green color).

PAs	<i>S. aureus</i>		<i>E. coli</i>	
	$N (\times 10^6)$	$K_b (\times 10^5)$	$N (\times 10^6)$	$K_b (\times 10^5)$
PA 4	7.97 ± 1.10	4.15 ± 0.42	1.32 ± 0.25	6.08 ± 0.83
PA 7	3.19 ± 0.59	2.87 ± 0.15	2.03 ± 0.11	8.06 ± 0.67
PA 12	41.51 ± 2.24	1.97 ± 0.14	0.97 ± 0.26	2.00 ± 0.11
PA 15	119.08 ± 5.37	0.57 ± 0.03	0.21 ± 0.03	0.23 ± 0.01

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4:

Cytotoxicity of designed PA against HaCaT, HCEC and HEK-293 and hemolytic activity against Human red blood cells.

PAs	IC ₅₀ (µg/mL)			HC ₅₀ (µg/mL)
	HaCaT ^a	HCEC ^b	HEK-293 ^c	Human red blood cells
PA 2	21.42	ne	>32	27.11
PA 3	17.59	ne	>32	8.31
PA 4	52.0	28.3	>32	22.3
PA 5	35.9	22.5	20.8	4.9
PA 8	40.4	19.3	>32	8.1
PA 11	37.1	18.7	20.3	16.1
PA 12	> 150	> 150	>32	>32
PA 13	> 150	27.5	>32	>32

^aImmortalized Human Keratinocyte;

^bImmortalized Human Colonic Epithelial Cell;

^cHuman embryonic kidney cells (ATCC CRL-1573).

HaCaT, HCEC cells were incubated with various PA concentration for 24 h and the cell viability was determined by MTT assay. Assays were performed in triplicate. Cytotoxicity against HEK-293 and Hemolytic Activity were performed by CO-ADD (The Community for Antimicrobial Drug Discovery), Australia.